[Application guidelines and research progress of biomarkers for Alzheimer's disease].

Alzheimer's disease (AD) is an age-related neurodegenerative disorder. It is expected that the incidence of AD will increase exponentially in the coming decades. The clinical and research application of AD biomarkers has gone through a long process. At present, the clinical diagnostic criteria for AD mainly include the IWG-2 criteria developed by International Working Group (IWG), the NIA-AA criteria formulated by the National Institute on Aging and Alzheimer's Association (NIA-AA) and the "Guidelines for the Diagnosis and Treatment of Alzheimer's Disease in China (2020 version)" released by the Professional Committee on Alzheimer's Disease and Related Diseases of the Chinese Geriatric Health Care Association (Alzheimer's Disease Chinese, ADC). Cerebrospinal fluid biomarkers such as Aβ42, T-tau and P-tau are recognized as central biomarkers for AD, besides, the development of new molecules in other pathophysiological pathway that can be used as biomarkers for the diagnosis of AD have made great progress in the last decade. This article elaborates studies of the application guidelines of AD biomarkers and highlights the research progress of biomarkers in AD pathophysiological pathway.阿尔茨海默病（AD）是一种与年龄相关的神经退行性疾病，预计在未来几十年，AD的发病率将呈指数增长。AD生物标志物的临床应用和相关指南的制定经历了漫长的历程。目前，临床应用的AD临床诊断标准主要包括国际工作组织（IWG）制定的IWG-2标准，美国国立老化研究所-阿尔茨海默病协会（NIA-AA）制定的NIA-AA标准和中国老年保健协会老年痴呆及相关疾病专业委员会（ADC）发布的《中国阿尔茨海默病痴呆诊疗指南（2020年版）》。另外，除了已经确立的脑脊液中的核心标志物包括Aβ42、T-tau和P-tau，其他分子病理学途径中可作为诊断AD的标志物的研究在近十年来取得显著进步。本文分别就AD生物标志物应用指南与AD病理进程相关生物标志物的研究进展进行阐述。.